Active Ingredient History

  • Now
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.   Wikipedia

  • SMILES: CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc3ccccc3C#N
  • Mol. Mass: 363.46
  • ALogP: 3.39
  • ChEMBL Molecules:
More Chemistry
benzonitrile, 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-, monohydrochloride | bucindolol | bucindolol hcl | bucindolol hydrochloride | mj 13105 | mj-13105-1


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue